Eligibility for filing a Roundup lawsuit in Georgia primarily extends to Georgia residents who have received a diagnosis of non-Hodgkin’s lymphoma (NHL) or certain other hematological (blood-related) cancers following a history of long-term, significant exposure to the herbicide Roundup.

Essential Qualification Factors:

• Diagnosis: The primary qualifying diagnosis is Non-Hodgkin’s Lymphoma (NHL). However, attorneys are also reviewing cases involving other cancers that studies have linked to glyphosate exposure, the active ingredient in Roundup.

• Exposure: A sustained, substantial duration of exposure is typically required. This often applies to agricultural workers, professional landscapers, groundskeepers, and frequent home/garden users who mixed, sprayed, or worked near the product over many years. Intermittent or minimal exposure is usually insufficient.

• Timing: The timing of the diagnosis relative to the exposure period is crucial. Generally, the exposure must have preceded the diagnosis by a medically relevant period.

No. While the new Georgia law passed in 2026 aims to provide certain legal defenses to manufacturers, it does not act as an outright bar to all Roundup claims.

The new legislation focuses primarily on failure-to-warn claims relating to the product's labeling. Specifically, if a manufacturer's label complies with federal requirements, such as those set by the Environmental Protection Agency (EPA), the manufacturer may gain certain protections against state-level claims alleging the label was inadequate.

Viable Claims that Remain Unaffected:

• Design Defects: Claims arguing that the inherent design of the product (the chemical composition itself) makes it unreasonably dangerous, regardless of the label, may still be pursued.

• Concealment of Risk: Cases presenting evidence that the manufacturer knowingly concealed, misrepresented, or actively suppressed scientific data demonstrating the health risks associated with Roundup remain viable and are often the cornerstone of ongoing litigation.

• Negligence: General negligence claims that are not solely dependent on the label's adequacy may also proceed.

It is critical to consult with an attorney experienced in mass tort litigation to assess how the specifics of the 2026 law might impact your unique case.

Yes. Like all civil actions, Roundup lawsuits in Georgia are subject to a strict deadline known as the Statute of Limitations.

Standard Timeline: Georgia typically requires personal injury and product liability claims to be filed within two years (24 months) of the date the cause of action accrued. In cancer cases, this is usually defined as the date of the non-Hodgkin’s lymphoma or relevant cancer diagnosis.

Potential Extensions (Tolling): Specific legal circumstances can sometimes "toll" or extend this two-year period. These exceptions are highly case-specific and may include:

• The Discovery Rule: If a patient was diagnosed but did not discover the link between their cancer and Roundup exposure until a later date, the clock may start running from the date of discovery.

• Status of the Plaintiff: Special rules may apply to minors or individuals deemed legally incompetent.

Given the complexity, potential claimants must seek legal advice immediately upon diagnosis to avoid missing this critical deadline.

If you were previously a member of the class action that resulted in the preliminary approval of the $7.25 billion class settlement (related to non-Hodgkin's lymphoma diagnosis), which was announced in March 2026, you face an important decision:

• Opt-In/Participate: By doing nothing, you automatically remain in the class, relinquish the right to file an individual lawsuit, and agree to receive compensation from the settlement fund, which may be significantly less than an individual verdict.

• Opt-Out/Exclude Yourself: You have a critical deadline of June 4, 2026, to officially "opt out" or exclude yourself from this settlement. Choosing to opt-out allows you to pursue your own individual claim against the manufacturer. Individual lawsuits allow the claimant to seek greater, personalized damages, though they carry the risk and expense of litigation.

It is strongly recommended that all eligible individuals consult with an attorney before June 4, 2026, to fully understand the financial implications of opting in versus opting out.